Showing 103,021 - 103,040 results of 106,197 for search '(( 3 point decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.91s Refine Results
  1. 103021

    Image_4_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  2. 103022

    Data_Sheet_1_CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients.docx by Anouk von Borstel (7421039)

    Published 2019
    “…</p><p>Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1–6.3). …”
  3. 103023

    Image_1_SEPT6_TRIM33 Gene Fusion and Mutated TP53 Pathway Associate With Unfavorable Prognosis in Patients With B-Cell Lymphomas.tif by Haiying Fu (1285074)

    Published 2021
    “…SEPT6_TRIM33 gene fusion, mutated TP53 and Hippo pathways were significantly associated with poor PFS, and SEPT6_TRIM33 fusion gene and mutated TP53 pathway were independent prognostic factors for B-cell lymphoma. A decreased VAF of TP53 p.Y88C and LATS2 p.F972L was detected in patients with complete response to treatments. …”
  4. 103024

    Image_6_Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recove... by Bernardo L. Rapoport (7431842)

    Published 2023
    “…Relative to a group of healthy control subjects (n=45), the median pre-treatment levels of five co-stimulatory (CD27, CD40, GITRL, ICOS, GITR) and three co-inhibitory (TIM-3, CTLA-4, PD-L1) soluble checkpoints were significantly lower in the BC patients vs. controls (p<0.021-p<0.0001; and p<0.008-p<0.00001, respectively). …”
  5. 103025
  6. 103026
  7. 103027
  8. 103028
  9. 103029

    Data Sheet 1_Exploring the therapeutic potential of “Zhi-Zhen” formula for oxaliplatin resistance in colorectal cancer: an integrated study combining UPLC-QTOF-MS/MS, bioinformatic... by Yongjing Li (3821944)

    Published 2025
    “…Background<p>Chemoresistance is a critical factor compromising the survival of patients with colorectal cancer (CRC). …”
  10. 103030
  11. 103031
  12. 103032
  13. 103033
  14. 103034
  15. 103035

    Table 3_Exploring the therapeutic potential of “Zhi-Zhen” formula for oxaliplatin resistance in colorectal cancer: an integrated study combining UPLC-QTOF-MS/MS, bioinformatics, ne... by Yongjing Li (3821944)

    Published 2025
    “…Background<p>Chemoresistance is a critical factor compromising the survival of patients with colorectal cancer (CRC). …”
  16. 103036
  17. 103037
  18. 103038
  19. 103039
  20. 103040